ANNX: Phase 2 showed dose-dependent vision protection; ARCHER II's 15-month analysis is targeted for Q4 2026

What happened

ARCHER Phase 2 showed dose-dependent reductions in confirmed 15-letter-or-greater vision loss, with the strongest result at the EM dose. ARCHER II enrolled 659 patients and targets its 15-month primary analysis in Q4 2026.

Confirmed

Global impact / market context

Annexon's eye-disease drug candidate showed stronger vision protection at higher doses in an earlier-stage trial. If the larger ARCHER II trial confirms this, the treatment could reach patients with a serious vision condition and give the company a valuable late-stage asset.

Analyst inference

Investors weigh early-stage signals against the risk that larger trials fail. ARCHER II's 659-patient enrollment and 15-month readout in Q4 2026 set a clear timeline, so attention likely shifts to execution and any safety or efficacy updates before that date.

Analyst inference

What to watch

1. ARCHER II's 15-month primary analysis is targeted for the fourth quarter of 2026, a date investors can track for the next major efficacy readout. Confirmed
2. Watch for company disclosures on dose selection and trial design for ARCHER II, since the Phase 2 strongest result was at the EM dose. Proposed
3. Any change to the ARCHER II timeline or early safety signals could shift views on the drug's chances, affecting how investors value Annexon's pipeline. Analyst inference

Evidence

• Original source link unavailable